In drug development today, therapies originally designed for one disease are being reimagined for broader use. Obesity treatments are becoming whole‑body therapeutics with cardiometabolic and psychiatric ambitions, for example. In gynecologic oncology, the emergence of checkpoint inhibitors alongside a growing field of antibody-drug conjugates is reshaping study design and bringing nuanced treatment sequencing decisions to…
Inside BioXcel Therapeutics’ AI-driven drug reinnovation strategy
Friso Postma, vice president of AI for drug discovery at BioXcel Therapeutics, prefers the term “augmented intelligence” to “artificial intelligence.” His company uses AI tools to support human experts in drug repurposing efforts. Postma, who holds a PhD in signal transduction from the Netherlands Cancer Institute, transitioned to AI from wearable digital health devices. “I…
Using AI to unlock new uses for existing cancer medicines
Repurposing is a drug development strategy that has been widely applied in cancer. This strategy, sometimes called label expansion, involves obtaining FDA approval to market a drug for the treatment of new indications, alone or in combination with other drugs. Not only can this approach extend the window of patent protection for a commercialized drug,…


